1
项与 德曲妥珠单抗生物类似药(台康生技股份有限公司) 相关的临床试验 / Not yet recruiting临床2期IIT A Phase II, Single-Arm, Bayesian Adaptive Study of Trastuzumab Deruxtecan in Combination With Stereotactic Radiosurgery in Patients With HER2-Positive Metastatic Breast Cancer and First Diagnosis of Brain Metastases (HERBRAIN)
This is a Phase II, single-arm, Bayesian adaptive trial. The study employs a two-stage design with an interim analysis after 30 evaluable patients and a maximum enrolment of 60 patients. T-DXd is administered at 5.4 mg/kg intravenously every 3 weeks until intracranial or systemic progression, unacceptable toxicity, or patient withdrawal. SRS (single-fraction) or fractionated stereotactic radiotherapy (fSRT, 3-5 fractions) is delivered within 21 days of enrolment, before Cycle 1 (with a minimum interval of 10 days from local treatment completion and Cycle 1 of T-DXd and a maximum interval of 28 days), for patients with 1-10 BMs and cumulative planning target volume ≤ 20.0 mL.
100 项与 德曲妥珠单抗生物类似药(台康生技股份有限公司) 相关的临床结果
100 项与 德曲妥珠单抗生物类似药(台康生技股份有限公司) 相关的转化医学
100 项与 德曲妥珠单抗生物类似药(台康生技股份有限公司) 相关的专利(医药)
100 项与 德曲妥珠单抗生物类似药(台康生技股份有限公司) 相关的药物交易